null - FindTrial

Pharmacokinetics study of piperacillin-tazobactam and meropenem in obese patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2013-000652-18-BE

Enrollment

Registered

2013-02-20

Start date

2013-03-19

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obese patients with an infection treated by broad spectrum B-lactams. MedDRA version: 14.1 Level: PT Classification code 10060945 Term: Bacterial infection System Organ Class: 10021881 - Infections and infestations

Interventions

Trade Name: Tazocin Pharmaceutical Form: Powder for solution for injection Other descriptive name: PIPERACILLIN Concentration unit: g gram(s) Concentration type: equal Concentration number: 4- Other d

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Patients >= 18 years -All hospitalized obese patient (BMI >= 30 kg/m²) treated by intraveinous piperacillin-tazobactam or meropenem for an infection (proven or suspected) -All hospitalized non-obese patient (BMI =65 years) yes F.1.3.1 Number of subjects for this age range 20

Exclusion criteria

Exclusion criteria: -Pregnant woman -Severe sepsis or septic shock

Design outcomes

Primary

Measure	Time frame
Main Objective: Determine the pharmacokinetics parameters of broad spectrum B-lactams (piperacillin-tazobactam and meropenem) given conventional doses in obese patients. ;Secondary Objective: Compare the result of obese patients with non-obese patients. ;Primary end point(s): -Determine optimal doses of B-lactams to administrer in obese patient -Determine any change of pharmacokinetics parameters of piperacillin-tazobactam and meropenem obesity-related and stratified by BMI ;Timepoint(s) of evaluation of this end point: NA	—

Measure

Time frame

Main Objective: Determine the pharmacokinetics parameters of broad spectrum B-lactams (piperacillin-tazobactam and meropenem) given conventional doses in obese patients. ;Secondary Objective: Compare the result of obese patients with non-obese patients. ;Primary end point(s): -Determine optimal doses of B-lactams to administrer in obese patient -Determine any change of pharmacokinetics parameters of piperacillin-tazobactam and meropenem obesity-related and stratified by BMI ;Timepoint(s) of evaluation of this end point: NA

—

Secondary

Measure	Time frame
Secondary end point(s): NA;Timepoint(s) of evaluation of this end point: NA	—

Countries

Belgium

Contacts

Public ContactRudy Surin

Hopital Erasme

rudy.surin@erasme.ulb.ac.be003225555807

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026